[Use of levamisole in the complex treatment of patients with thyrotoxicosis]. 1986

N I Afanas'eva, and V V Natarov, and T S Grinchenko

The immune status was studied in patients with a familial nature of thyrotoxicosis and without complicated heredity. Disorders in the immune homeostasis, mostly expressed in thyrotoxicosis of familial nature, were revealed. Proceeding from the above the authors proposed a method of multimodality therapy of thyrotoxicosis with antithyroid drugs and immunomodulator levamisole causing a fast disappearance of the clinical signs of thyrotoxicosis, a decrease in thyroid activity and density and the reduction of the number of surgical interventions. The effect may be probably due to the normalization of the immune status.

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D004105 Diiodotyrosine A product from the iodination of MONOIODOTYROSINE. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Iodogorgoic Acid,Acid, Iodogorgoic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D013971 Thyrotoxicosis A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING. Thyrotoxicoses

Related Publications

N I Afanas'eva, and V V Natarov, and T S Grinchenko
November 1985, Akusherstvo i ginekologiia,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
May 1986, Gematologiia i transfuziologiia,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
August 1984, Voenno-meditsinskii zhurnal,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1986, Terapevticheskii arkhiv,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1971, Vutreshni bolesti,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1982, Terapevticheskii arkhiv,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1982, Sovetskaia meditsina,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
March 1986, Klinicheskaia meditsina,
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1987, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
N I Afanas'eva, and V V Natarov, and T S Grinchenko
January 1986, Terapevticheskii arkhiv,
Copied contents to your clipboard!